

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED

銘源醫療發展有限公司*

(Incorporated in Bermuda with limited liability)

(Stock code: 0233)

INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by Mingyuan Medicare Development Company Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance. Capitalised terms used herein shall have the same meaning ascribed to in the announcement of the Company dated 25 September 2014 (the “**25/9/2014 Announcement**”).

Reference is made to the 25/9/2014 Announcement in which the Company (under the then management) announced a Writ was issued at the High Court of the Hong Kong Special Administrative Region by Chien as the Plaintiff against the Company as the Defendant for payment of director’s fee, housing allowance, reimbursement of expenses, special bonus and interest in the Litigation, namely, HCA 1837 of 2014.

After the change of the management of the Company effective on 20 May 2016, the Company has sought independent legal advice on the Litigation. The solicitors firm representing the Company in the Litigation signed a consent summons with the Solicitors for Chien on 25 October 2016 (the “**Consent Summons**”) to the effect that Chien’s claim and the Company’s counterclaim in the Litigation be dismissed with no order as to costs of the Litigation.

On 27 October 2016, the Court, by consent, ordered in terms as amended of the Consent Summons. As a result, Chien’s action and the Company’s counterclaim in the Litigation were ordered to be dismissed, and the Litigation has therefore come to an end.

** For identification purpose only*

Trading in shares of the Company will remain suspended pending satisfaction of the resumption conditions imposed by the Stock Exchange.

By Order of the Board
Mingyuan Medicare Development Company Limited
LAM Ping Cheung
Chairman

Hong Kong, 1 November 2016

As at the date of this announcement, the Board comprises (i) Mr. Lam Ping Cheung and Mr. Hui Yip Wing as executive Directors; (ii) Ms. Lam Yan Fong Flora as non-executive Director; and (iii) Ms. Chan Mee Sze, Ms. Hui Wai Man Shirley, Mr. Lam Suk Ping and Mr. Wong Anthony Chi-ho as independent non-executive Directors.